title: Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression.
abstract: Mucin 1 (MUC1) is a type I transmembrane glycoprotein abundantly expressed on nearly all epithelial tissues and overexpressed by many cancer cells. Previous studies from our lab showed that progesterone receptor (PR)B is a strong stimulator of MUC1 gene expression. It is reported that liganded peroxisome proliferator-activated receptor gamma (PPARgamma) stimulates Muc1 expression in murine trophoblast. Here, we demonstrate that although the PPARgamma ligand, rosiglitazone, stimulates the murine Muc1 promoter in HEC1A, a human uterine epithelial cell line, rosiglitazone alone, has no significant effect on basal human MUC1 promoter activity. In fact, rosiglitazone treatment antagonizes progesterone-stimulated human MUC1 promoter activity and protein expression in two human uterine epithelial cell lines and T47D human breast cancer cells. This response is antagonized by the PPARgamma antagonist, GW9662, as well as a dominant-negative form of PPARgamma, demonstrating the response is mediated by PPARgamma. Additional studies indicate that PPARgamma activation does not change PR binding to the MUC1 promoter but generally antagonizes progesterone activity by stimulating PRB degradation and inhibiting progesterone-induced PRB phosphorylation. Collectively, these studies indicate that PPARgamma activation inhibits PRB activity through both acute (phosphorylation) and long-term (PRB degradation) pathways.
authors.affiliation: Department of Biological Sciences, University of Delaware, Newark, Delaware 19716, USA.
authors.forename: Peng
authors.initials: P
authors.lastname: Wang
authors.forename: Neeraja
authors.initials: N
authors.lastname: Dharmaraj
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Brayman
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Carson
mesh_terms: D000813:Anilides / Q000494:pharmacology; D015153:Blotting, Western; D045744:Cell Line, Tumor; D047369:Chromatin Immunoprecipitation; D006801:Humans; D018396:Mucin-1 / Q000235:genetics / Q000378:metabolism*; D047493:PPAR alpha / Q000819:agonists / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D011374:Progesterone / Q000494:pharmacology*; D011401:Promoter Regions, Genetic / Q000187:drug effects; D011485:Protein Binding / Q000187:drug effects; D011980:Receptors, Progesterone / Q000378:metabolism; D047488:Retinoid X Receptors / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: C457499:2-chloro-5-nitrobenzanilide; D000813:Anilides; D018396:Mucin-1; D047493:PPAR alpha; D047495:PPAR gamma; D011980:Receptors, Progesterone; D047488:Retinoid X Receptors; D045162:Thiazolidinediones; C097314:progesterone receptor B; D000077154:Rosiglitazone; D011374:Progesterone